Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AUPH Aurinia Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AUPH
Price (delayed)
$8
Market cap
$1.1B
P/E Ratio
200
Dividend/share
N/A
EPS
$0.04
Enterprise value
$1.09B
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
Highlights
Aurinia Pharmaceuticals's EPS has surged by 129% QoQ and by 107% YoY
The net income has soared by 126% from the previous quarter and by 107% YoY
The quick ratio has declined by 18% since the previous quarter and by 17% year-on-year
The gross margin has declined by 4.2% year-on-year
Key stats
What are the main financial stats of AUPH
Market
Valuations
Earnings
Shares outstanding
137.34M
Market cap
$1.1B
Enterprise value
$1.09B
Price to earnings (P/E)
200
Price to book (P/B)
3.03
Price to sales (P/S)
4.87
EV/EBIT
89.12
EV/EBITDA
34.5
EV/Sales
4.66
Revenue
$235.13M
Gross profit
$206.89M
Operating income
-$4.69M
Net income
$5.75M
EBIT
$12.28M
EBITDA
$31.73M
Free cash flow
$44.11M
Per share
Balance sheet
Liquidity
EPS
$0.04
EPS diluted
$0.04
Free cash flow per share
$0.31
Book value per share
$2.64
Revenue per share
$1.64
TBVPS
$3.82
Total assets
$550.65M
Total liabilities
$173.17M
Debt
$79.37M
Equity
$377.48M
Working capital
$348.83M
Debt to equity
0.21
Current ratio
4.57
Quick ratio
4.04
Net debt/EBITDA
-0.13
Margins
Efficiency
Dividend
EBITDA margin
13.5%
Gross margin
88%
Net margin
2.4%
Operating margin
-2%
Return on assets
1.1%
Return on equity
1.5%
Return on invested capital
2.6%
Return on capital employed
2.7%
Return on sales
5.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUPH stock price
How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
-1.36%
1 week
-2.56%
1 month
5.12%
1 year
54.74%
YTD
-10.91%
QTD
-0.5%
Financial performance
How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$235.13M
Gross profit
$206.89M
Operating income
-$4.69M
Net income
$5.75M
Gross margin
88%
Net margin
2.4%
The net income has soared by 126% from the previous quarter and by 107% YoY
Aurinia Pharmaceuticals's net margin has surged by 124% QoQ and by 105% YoY
The operating margin has soared by 96% YoY and by 86% from the previous quarter
The operating income has soared by 95% year-on-year and by 86% since the previous quarter
Price vs fundamentals
How does AUPH's price correlate with its fundamentals
Growth
What is Aurinia Pharmaceuticals's growth rate over time
Valuation
What is Aurinia Pharmaceuticals stock price valuation
P/E
200
P/B
3.03
P/S
4.87
EV/EBIT
89.12
EV/EBITDA
34.5
EV/Sales
4.66
Aurinia Pharmaceuticals's EPS has surged by 129% QoQ and by 107% YoY
The price to book (P/B) is 24% lower than the 5-year quarterly average of 4.0 but 17% higher than the last 4 quarters average of 2.6
AUPH's equity is down by 2.7% since the previous quarter
The stock's P/S is 100% less than its 5-year quarterly average of 1129.6 but 8% more than its last 4 quarters average of 4.5
The revenue has increased by 34% YoY and by 7% from the previous quarter
Efficiency
How efficient is Aurinia Pharmaceuticals business performance
AUPH's ROIC has soared by 187% since the previous quarter and by 116% year-on-year
Aurinia Pharmaceuticals's return on sales has surged by 175% QoQ and by 112% YoY
The company's return on assets has surged by 126% QoQ and by 107% YoY
The ROE has soared by 125% from the previous quarter and by 107% YoY
Dividends
What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUPH.
Financial health
How did Aurinia Pharmaceuticals financials performed over time
Aurinia Pharmaceuticals's current ratio has decreased by 18% from the previous quarter and by 17% YoY
The quick ratio has declined by 18% since the previous quarter and by 17% year-on-year
Aurinia Pharmaceuticals's debt is 79% lower than its equity
Aurinia Pharmaceuticals's debt has decreased by 19% YoY and by 10% QoQ
The company's debt to equity fell by 19% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.